Citadel Advisors
UTMD icon

Citadel Advisors’s Utah Medical Products UTMD Stock Holding History

Citadel Advisors’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,954
Closed -$613K – 14297
2025
Q4 		$613K Buy
+10,954
New +$635K ﹤0.01% 8544
2025
Q3 		– Sell
-9,367
Closed -$533K – 14194
2025
Q2 		$533K Sell
9,367
-16,528
-64% -$899K ﹤0.01% 8479
2025
Q1 		$1.45M Buy
25,895
+15,892
+159% +$952K ﹤0.01% 6155
2024
Q4 		$615K Sell
10,003
-6,918
-41% -$447K ﹤0.01% 8093
2024
Q3 		$1.13M Sell
16,921
-3,849
-19% -$261K ﹤0.01% 6636
2024
Q2 		$1.39M Sell
20,770
-18,448
-47% -$1.26M ﹤0.01% 5983
2024
Q1 		$2.79M Buy
39,218
+32,087
+450% +$2.41M ﹤0.01% 4910
2023
Q4 		$601K Buy
7,131
+2,522
+55% +$209K ﹤0.01% 7695
2023
Q3 		$396K Sell
4,609
-4,472
-49% -$413K ﹤0.01% 8580
2023
Q2 		$846K Sell
9,081
-323
-3% -$30.4K ﹤0.01% 6805
2023
Q1 		$891K Buy
9,404
+6,008
+177% +$552K ﹤0.01% 7033
2022
Q4 		$341K Buy
3,396
+883
+35% +$80.6K ﹤0.01% 9032
2022
Q3 		$214K Buy
+2,513
New +$222K ﹤0.01% 10284
2022
Q2 		– Sell
-4,451
Closed -$400K – 14165
2022
Q1 		$400K Buy
4,451
+2,128
+92% +$196K ﹤0.01% 9902
2021
Q4 		$233K Buy
+2,323
New +$237K ﹤0.01% 11531
2020
Q4 		– Sell
-2,833
Closed -$227K – 11554
2020
Q3 		$227K Sell
2,833
-432
-13% -$35.8K ﹤0.01% 8615
2020
Q2 		$290K Sell
3,265
-1,383
-30% -$124K ﹤0.01% 7963
2020
Q1 		$437K Buy
4,648
+2,530
+119% +$235K ﹤0.01% 6690
2019
Q4 		$229K Sell
2,118
-586
-22% -$59.4K ﹤0.01% 7993
2019
Q3 		$259K Buy
+2,704
New +$251K ﹤0.01% 7781
2018
Q4 		– Sell
-2,411
Closed -$227K – 9798
2018
Q3 		$227K Buy
+2,411
New +$230K ﹤0.01% 8023

Other funds holding UTMD

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $155M AUM 35.49% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's UTMD Position: Q1 2026 in Review

Citadel Advisors sold out of Utah Medical Products (UTMD) in Q1 2026, closing a stake of 10,954 shares — an estimated $613K sold.

Citadel Advisors first reported a position in UTMD in Q3 2018 and held it in 21 quarters. The position peaked at $2.79M in Q1 2024. 119 funds tracked by Wall St. Rank hold UTMD as of Q1 2026.

  • Citadel Advisors reported no remaining Utah Medical Products position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 10,954 Utah Medical Products shares in Q1 2026, an estimated $613K.
  • Citadel Advisors first reported a position in Utah Medical Products in Q3 2018 and held it in 21 quarters.
  • Citadel Advisors's Utah Medical Products position peaked at $2.79M in Q1 2024.
  • 119 funds tracked by Wall St. Rank held Utah Medical Products as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.